Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer

Study:

Evaluation of CSF Levels of Tarceva (OSI-774) in Patients With Stage III Non-Small Cell Lung Cancer and No CNS Involvement Undergoing Treatment With Tarceva

Rationale:

Determining whether erlotinib passes into the cerebrospinal fluid may help in planning treatment for some types of cancer.

Purpose:

This clinical trial is studying how well erlotinib is able to pass into the cerebrospinal fluid of patients receiving erlotinib for stage III non-small cell lung cancer.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Lung Cancer Other: antitumor drug screening assay N/A

Verified by The Cleveland Clinic July, 2009

Sponsored by: The Cleveland Clinic
Information provided by: The Cleveland Clinic
ClinicalTrials.gov identifier: NCT00305617

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Primary Purpose: Diagnostic

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Michael A. Vogelbaum, MD, PhD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site